{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-002828","form_type":"8-K","ticker":"REVB","cik":"0001810560","company_name":"REVELATION BIOSCIENCES, INC.","filed_at":"2025-01-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.974036+00:00","generated_at":"2026-05-28T08:51:38.446240+00:00","sec_items":["3.01","8.01","9.01"],"event_type":"regulatory","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Nasdaq grants Revelation continued listing subject to reverse split and $1 price by Feb 14, 2025","bullets":["Nasdaq Panel granted continued listing; must effect reverse stock split by Jan 31, 2025.","Must maintain $1.00 bid price for 10 consecutive trading days by Feb 14, 2025.","Regained compliance with Nasdaq equity requirement (Rule 5550(b)(1)).","Company raised $4M from warrant exercise in December 2024.","FDA accepted Gemini IND; Phase 1b study in chronic kidney disease expected H1 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-002828","json":"https://secwatch.observer/filing/0000950170-25-002828.json","markdown":"https://secwatch.observer/filing/0000950170-25-002828.md","text":"https://secwatch.observer/filing/0000950170-25-002828.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1810560/000095017025002828/0000950170-25-002828-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1810560/000095017025002828/revb-20250103.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T08:51:38.446240+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"390a5432ddd13787cba36c324c76aeffc0184096","claim":"REVELATION BIOSCIENCES, INC. received a nasdaq compliance regained notice regarding stockholders equity (rules 5550(b)(1)).","evidence_excerpt":"January 3, 2025, Revelation Biosciences, Inc. (the “Company”) received a decision letter issued by the Nasdaq Hearings Panel granting the Company’s request to continue its listing on The Nasdaq Stock Market, subject to e","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1810560/000095017025002828/0000950170-25-002828-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"compliance regained"},{"label":"Deficiency","value":"stockholders equity"},{"label":"Rules","value":"5550(b)(1)"}],"fact_type":"exchange_compliance_notice"},{"claim_id":"7a6bcf89612c290215ba8a957cb222e8384e0fbe","claim":"REVELATION BIOSCIENCES, INC. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).","evidence_excerpt":"January 3, 2025, Revelation Biosciences, Inc. (the “Company”) received a decision letter issued by the Nasdaq Hearings Panel granting the Company’s request to continue its listing on The Nasdaq Stock Market, subject to e","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1810560/000095017025002828/0000950170-25-002828-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"extension granted"},{"label":"Deficiency","value":"minimum bid price"},{"label":"Rules","value":"5550(a)(2)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}